Johnson & Johnson (JNJ) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.59
- Estimate
- $2.52
- Surprise
- +2.7%
- Score at report (before → after)
- 5.3 → 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Johnson & Johnson (JNJ) beat the $2.52 estimate with adjusted EPS of $2.59 — a modest 2.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Hold at 5.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates JNJ Hold at 5.0/10.
3 of the last 4 quarters beat the estimate; this quarter's +2.7% surprise compares with a +1.3% four-quarter average. Next scheduled report: 2027-01-26.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.0 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Weak overall score: 5.0/10
- Expensive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $267.49
- Stop
- $254.05
The stock trades at 41.1× trailing but 23.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
JNJ at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $651.32B
- P/E (fwd)
- 23.3
- P/E (ttm)
- 41.1
- 52-week range
- $185.12–$282.02
- Off 52-week high
- 5.2%
- RSI (14)
- 65
- Volume vs avg
- 0.36×
- Score today
- 5.0/10